COMPARATIVE STUDY ON THE EFFICACY OF MOMETASONE AND FLUTICASONE NASAL SPRAYS FOR TREATMENT OF ALLERGIC RHINITIS

MAHSHID SADAT MIRMOEZZI1, MOHAMMAD SHURIDEH YAZDI2, OMID GHOLAMI3*

1Medical Student at the Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran, 2Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran, 3Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

Email:omidghphd@gmail.com

Received: 31 Oct 2016 Revised and Accepted: 30 Jan 2017

ABSTRACT

Objective: Allergic rhinitis is the most prevalent of allergic diseases in the world. Nasal corticosteroids are the most applicable drugs for the treatment of allergic rhinitis. In this study, we compared the efficacy of fluticasone propionate (FP) and mometasone furoate (MF) nasal sprays in the treatment of allergic rhinitis based on total nasal symptom score (TNSS) questionnaire.

Methods: For this study, 75 allergic rhinitis patients based on skin prick test and inclusion criteria were randomly assigned to two groups: FP and MF groups. FP group received 200 µg dose of FP nasal spray (1 spray/nostril) daily and the MF group received 100 mg dose of MF nasal spray (1 spray/nostril) daily for 8 w. The effects of the two agents were compared based on TNSS questionnaire in 0, 4 and 8 w after the beginning of the treatment.

Results: Results showed that patients in both groups exhibited significant improvement in their TNSS (P Value<0.001). A detailed TNSS analysis showed MF to be more effective for relieving all symptoms than FP. The most difference is in decreasing postnasal discharge (PND) symptom. However, the difference for relieving all symptoms is not significant (P value>0.05).

Conclusion: In conclusion, FP and MF are significantly effective in relieving of allergic rhinitis symptoms. Even though, the difference between the two is not significant for 8 w therapy.

Keywords: Fluticasone Propionate, Mometasone Furoate, Allergic Rhinitis, Total Nasal Symptom Score (TNSS) questionnaire

INTRODUCTION

Allergic rhinitis represents a global health problem that affects 10 to 20% of the population [1]. Allergic rhinitis is a type I hypersensitivity reaction to exogenous substances like a plant or animal allergens. In this type of reaction, the cutaneous, mucosal-cutaneous or anaphylactic reaction occurs immediately or several minutes after exposure. Diagnostic criteria of allergic rhinitis are recurrent chronic nasal symptoms such as congestion, rhinorrhea (often including postnasal drip), nasal itching, sneezing, and conjunctiva irritation [2]. Allergic rhinitis causes sleep disturbance, impairs psychosocial functioning, and reduces life quality [3].

Allergic rhinitis treatment includes allergen avoidance, pharmacotherapy, and immunotherapy. Intranasal corticosteroids are recommended as first-line therapy for patients with moderate-to-severe Allergic Rhinitis, especially when nasal congestion is a major component of symptoms [4]. To compare the efficacy and safety profile of different available Intranasal corticosteroids for the treatment of Allergic Rhinitis, it is important to understand the difference in chemical structures, their pharmacokinetic and pharmacodynamics properties [4].

Chemical structure of fluticasone and mometasone are displayed in fig. 1. Relative receptor affinity of MF is greater than FP (2244 vs. 1775) [4]. As pharmacokinetic properties, the bioavailability of MF is more than FP (46% vs. 42%), and Fraction of unbound intranasal FP in plasma is more than MF (0.1 vs. 0.01) [5]. Based on these pharmacodynamics/pharmacokinetic properties, we respect to have a better clinical outcome for MF than FP.

Fig. 1: Structure of mometasone (A) vs. fluticasone (B) [6]

Despite numerous articles about the efficacy of FP and MF nasal spray exist, there is no research about the comparing of the efficacy of these two drugs.

Based on these data, comparing the efficacy of FP and MF on allergic rhinitis symptoms based on TNSS questionnaire is the aim of this manuscript.
MATERIALS AND METHODS

Participants
This study was conducted in the Division of Otolaryngology, Head and Neck Surgery at Vasei Medical University Hospital, Sabzevar, Iran, between August 2015 and March 2016. The study was approved by the vice chancellor for research of Sabzevar University of Medical Sciences and Iranian Registry for Clinical Trials (IRCT2016031419240N2), and written consent was obtained prior to commencement. The study did not receive the MF and FP Corporate Support Grant.

The inclusion criteria were: 1) persistent of Allergic Rhinitis (defined based on clinical examination and verified questionnaire) 2) a positive reaction confirmed by a skin-prick test response. In positive skin-prick test responses, the skin becomes red and swollen with a wheal>3 mm in diameter.

The exclusion criteria were: 1) infection in the 2 w preceding the initial visit; 2) upper and lower respiratory tract infection within 2 w prior to the study; 3) medication consumption that may affect allergy symptoms (such as oral antihistamines, decongestants, steroids, or leukotriene antagonists) within 2 w prior to the study or during the study period; 4) intranasal corticosteroid use within 2 w prior to the study; and 5) nasal polyp disease.

In total, 75 patients with allergic rhinitis met the inclusion criteria for this study.

Study design
In the initial screening visit, comprehensive medical and allergy histories were obtained for all participants. Daily-activity diaries were provided to the participants, with instructions to record all symptoms once treatment began. The diaries of patient activity for the preceding 7 d were also reviewed.

The study design was randomised, prospective, single-blind and controlled. The participants were randomly divided into two groups each participant received a unique code. Of the 75 participants, 6 cases were excluded during the study (2 cases from FP group and 4 cases from MF group), 36 cases received FP nasal spray (FP group), and 33 cases received MF nasal spray (MF group). FP group received a 200 µg dose of FP nasal spray (1 spray/nostril) daily for 8 w, and the remaining participants (MF group) received a 100 µg dose of MF nasal spray (1 spray/nostril) daily for 8 w.

Total nasal symptom score (TNSS)
Rhinitis symptoms were measured using a 4-point scale. Scores as follows: 0 denoted "none" (no noticeable symptoms); 1 denoted "mild" (symptoms are noticeable but not bothersome); 2 denoted "moderate" (symptoms are noticeable and occasionally bothersome but do not disturb daily activities and sleep); and 3 denoted "severe" (symptoms are generally bothersome and disturb daily activities and sleep). The examiner recorded the patient scores for six nasal symptoms (nasal congestion, rhinorrhea, postnasal drip (PND), nasal itching, smelling disorder and sneezing). Baseline TNSS and each symptom score were calculated as the mean of the scores after 0, 4 and 8 w of initiation of treatment [7].

Statistics
Statistical analysis was performed using IBM SPSS statistics software. All data are expressed as mean±standard deviation. An independent sample t-test was used to compare the improvement rates of the mean TNSS for the two groups. A p value<0.05 was considered statistically significant. A paired t-test was used to compare the improvement rates of the mean TNSS for each group from w0 to w4 and w8. A p value<0.001 was considered statistically significant.

RESULTS
A total of 75 patients were enrolled in this study, with 36 patients assigned to an FP group and 33 patients assigned to an MF group. However, 6 patients with incomplete TNSS recordings during the treatment period were subsequently excluded from this study. The mean age of the patients was 21.46 (9.624) years (for FP group) and 20.136 (9.198) years (for MF group). No significant differences were observed between the two groups for baseline demographics or health characteristics (table 1).

Fig. 1: Total nasal symptom scores (TNSS) in W0, W4 and W8 (**p<0.001)

Fig. 2: Mean value of total nasal symptom score (TNSS) in W0, W4 and W8 (**p<0.001)

For both the FP and MF groups, we analyzed the change in TNSS from baseline (W 0) to Ws 4 and 8 of the treatment. The TNSS was

The study was conducted in the Division of Otolaryngology, Head and Neck Surgery at Vasei Medical University Hospital, Sabzevar, Iran, between August 2015 and March 2016. The study was approved by the vice chancellor for research of Sabzevar University of Medical Sciences and Iranian Registry for Clinical Trials (IRCT2016031419240N2), and written consent was obtained prior to commencement. The study did not receive the MF and FP Corporate Support Grant.

The inclusion criteria were: 1) persistent of Allergic Rhinitis (defined based on clinical examination and verified questionnaire) 2) a positive reaction confirmed by a skin-prick test response. In positive skin-prick test responses, the skin becomes red and swollen with a wheal>3 mm in diameter.

The exclusion criteria were: 1) infection in the 2 w preceding the initial visit; 2) upper and lower respiratory tract infection within 2 w prior to the study; 3) medication consumption that may affect allergy symptoms (such as oral antihistamines, decongestants, steroids, or leukotriene antagonists) within 2 w prior to the study or during the study period; 4) intranasal corticosteroid use within 2 w prior to the study; and 5) nasal polyp disease.

In total, 75 patients with allergic rhinitis met the inclusion criteria for this study.

Study design
In the initial screening visit, comprehensive medical and allergy histories were obtained for all participants. Daily-activity diaries were provided to the participants, with instructions to record all symptoms once treatment began. The diaries of patient activity for the preceding 7 d were also reviewed.

The study design was randomised, prospective, single-blind and controlled. The participants were randomly divided into two groups each participant received a unique code. Of the 75 participants, 6 cases were excluded during the study (2 cases from FP group and 4 cases from MF group), 36 cases received FP nasal spray (FP group), and 33 cases received MF nasal spray (MF group). FP group received a 200 µg dose of FP nasal spray (1 spray/nostril) daily for 8 w, and the remaining participants (MF group) received a 100 µg dose of MF nasal spray (1 spray/nostril) daily for 8 w.

Total nasal symptom score (TNSS)
Rhinitis symptoms were measured using a 4-point scale. Scores as follows: 0 denoted "none" (no noticeable symptoms); 1 denoted "mild" (symptoms are noticeable but not bothersome); 2 denoted "moderate" (symptoms are noticeable and occasionally bothersome but do not disturb daily activities and sleep); and 3 denoted "severe" (symptoms are generally bothersome and disturb daily activities and sleep). The examiner recorded the patient scores for six nasal symptoms (nasal congestion, rhinorrhea, postnasal drip (PND), nasal itching, smelling disorder and sneezing). Baseline TNSS and each symptom score were calculated as the mean of the scores after 0, 4 and 8 w of initiation of treatment [7].

Statistics
Statistical analysis was performed using IBM SPSS statistics software. All data are expressed as mean±standard deviation. An independent sample t-test was used to compare the improvement rates of the mean TNSS for the two groups. A p value<0.05 was considered statistically significant. A paired t-test was used to compare the improvement rates of the mean TNSS for each group from w0 to w4 and w8. A p value<0.001 was considered statistically significant.

RESULTS
A total of 75 patients were enrolled in this study, with 36 patients assigned to an FP group and 33 patients assigned to an MF group. However, 6 patients with incomplete TNSS recordings during the treatment period were subsequently excluded from this study. The mean age of the patients was 21.46 (9.624) years (for FP group) and 20.136 (9.198) years (for MF group). No significant differences were observed between the two groups for baseline demographics or health characteristics (table 1).

Table 1: Demography of characteristics and baseline data of the both fluticasone propionate (FP) and mometasone furoate (MF) groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>FP group</th>
<th>MF group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>36</td>
<td>33</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>17 (47.2%)</td>
<td>16 (48.5%)</td>
</tr>
<tr>
<td>Female</td>
<td>19 (52.8%)</td>
<td>17 (51.5%)</td>
</tr>
<tr>
<td>Age (y)</td>
<td>21.46 (9.624)</td>
<td>20.136 (9.198)</td>
</tr>
</tbody>
</table>

Data are presented as n (%) or mean (standard deviation)

For both the FP and MF groups, we analyzed the change in TNSS from baseline (W 0) to Ws 4 and 8 of the treatment. The TNSS was
and were well tolerated [8]. Their results are in harmony with our results. In a recent study, Yonezaki et al. found that fluticasone furoate was significantly preferred over mometasone furoate in allergic rhinitis [16]. Their results are not consistent with our results.

In another study, researchers found that following the 4-w therapy, mometasone furoate (MF) nasal spray provided greater improvement compared to fluticasone propionate (FP) nasal spray for symptoms of childhood perennial allergic rhinitis. Based on their Total Symptom Scores (TSSs) questionnaire, the MF group experienced more effective relief of nasal symptoms, whereas the FP group experienced more effective relief of non-nasal symptoms [2].

### Table 2: Changes in total nasal symptom score from baseline (W0) of individual symptoms

<table>
<thead>
<tr>
<th>Nasal Symptoms</th>
<th>Fluticasone propionate group</th>
<th>Mometasone furoate group</th>
</tr>
</thead>
<tbody>
<tr>
<td>W0-W4</td>
<td>-1.385 (0.815)</td>
<td>-1.821 (0.548)</td>
</tr>
<tr>
<td>W0-W8</td>
<td>-1.821 (0.79)</td>
<td>-2.321 (0.67)</td>
</tr>
<tr>
<td>W4-W8</td>
<td>-0.436 (0.502)</td>
<td>-0.5 (0.509)</td>
</tr>
<tr>
<td>Rhinorrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W0-W4</td>
<td>-1.513 (0.854)</td>
<td>-1.679 (0.67)</td>
</tr>
<tr>
<td>W0-W8</td>
<td>-1.795 (0.695)</td>
<td>-1.964 (0.508)</td>
</tr>
<tr>
<td>W4-W8</td>
<td>-0.282 (0.456)</td>
<td>-0.286 (0.46)</td>
</tr>
<tr>
<td>PND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W0-W4</td>
<td>-0.897 (0.598)</td>
<td>-1.286 (0.6)</td>
</tr>
<tr>
<td>W0-W8</td>
<td>-1.051 (0.605)</td>
<td>-1.357 (0.559)</td>
</tr>
<tr>
<td>W4-W8</td>
<td>-0.154 (0.366)</td>
<td>-0.071 (0.262)</td>
</tr>
<tr>
<td>Nasal itching</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W0-W4</td>
<td>-1.487 (0.823)</td>
<td>-1.714 (0.713)</td>
</tr>
<tr>
<td>W0-W8</td>
<td>-1.59 (0.818)</td>
<td>-1.893 (0.786)</td>
</tr>
<tr>
<td>W4-W8</td>
<td>-0.103 (0.307)</td>
<td>-0.179 (0.39)</td>
</tr>
<tr>
<td>Smelling disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W0-W4</td>
<td>-1.128 (0.656)</td>
<td>-1.357 (0.731)</td>
</tr>
<tr>
<td>W0-W8</td>
<td>-1.538 (0.822)</td>
<td>-1.643 (0.911)</td>
</tr>
<tr>
<td>W4-W8</td>
<td>-0.41 (0.549)</td>
<td>-0.286 (0.46)</td>
</tr>
<tr>
<td>Sneezing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W0-W4</td>
<td>-1.41 (0.85)</td>
<td>-1.393 (0.685)</td>
</tr>
<tr>
<td>W0-W8</td>
<td>-1.538 (0.822)</td>
<td>-1.644 (0.744)</td>
</tr>
<tr>
<td>W4-W8</td>
<td>-0.128 (0.339)</td>
<td>-0.071 (0.262)</td>
</tr>
</tbody>
</table>

Data are presented as mean±standard deviation

This study was subject to several limitations. First, recall bias contributed to the inconsistent TNSS results. It is better to employ various examinations, such as nasal peak expiratory flow rate (nPEFR) and the eosinophil percentage in nasal smears, to reduce questionnaire bias. Second, we did not classify the severity of patients’ allergic rhinitis in this study; otherwise, the possible response differences to treatment for mild persistent, severe intermittent, or severe persistent types of allergic rhinitis could have been analyzed. At last, we lacked patient data on family member smoking habits and household pets, which are factors that may affect allergic rhinitis symptoms [9].

### CONCLUSION

Our study results show that both intranasal corticosteroid sprays (FP and MF) were effective for managing allergic rhinitis. FP and MF treatment were associated with a significant improvement in mean TNSS (P value<0.001). A further detailed analysis of TNSS indicated that MF was more effective than FP for relieving nasal symptoms (except sneezing, table 2), but this difference was not significant.

In conclusion, the results of our 8-w treatment program showed that FP and MF nasal sprays were effective for improving the symptoms of allergic rhinitis significantly. Although the TNSS for the FP and MF group did not show a significant difference between them.

### ACKNOWLEDGMENT

This study is part of Mahshid Sadat Mimoeezii M. D. thesis titled: “Comparison of Mometasone Fumate and Fluticasone Propionate Nasal Sprays in the Treatment of Allergic Rhinitis”, which has been conducted in the faculty of medicine, Sabzevar University of Medical Sciences.

This Research Project was fully sponsored by Vice Chancellor for Research of Sabzevar University of Medical Sciences with grant number “393010173”. The study did not receive the MF and FP Corporate Support Grant.

The funding organization is a public institution and had no role in the design and conduct of the study; collection, management, and analysis of the data; or preparation, review, and approval of the manuscript.

### CONFLICTS OF INTERESTS

We certify that no actual or potential conflict of interest in relation to this article exists.

### REFERENCES


How to cite this article